Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers (ECHO-202/KEYNOTE-037)

NCT02178722 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT02178722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02178722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers (ECHO-202/KEYNOTE-037)
Lead sponsor
Incyte Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
July 17, 2014
Completion date
November 6, 2020
Enrollment
444 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, endometrial cancer, gastric cancer, head and neck cancer, hepatocellular carcinoma (hcc), lung cancer, lymphoma, melanoma, microsatellite-instability (msi) high colorectal cancer (crc), ovarian cancer, renal cell carcinoma (rcc), solid tumors, triple negative breast cancer (tnbc), uc (urothelial cancer)